Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To the Editor Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for relapsed and refractory multiple myeloma (RRMM), but its wider use has renewed attention to off-target toxicities.
Results We recruited a real-world cohort of 61 RRMM patients treated with BCMA-directed CAR T cells at our center. Samples of 57 patients were available for single-cell multi-omics profiling: A total of 135 peripheral blood mononuclear cell (PBMC) samples at 3 different time points were collected for single cell RNA, B cell receptor (BCR), TCR and surface protein profiling.
PET/CT plays an important role in staging of multiple myeloma (MM) and detecting extramedullary disease (EMD); however, its role in patients treated with commercially available CAR T cell therapies is unclear. We evaluated 61 patients treated with CAR T cell products. In 53 patients, PET/CT was available before CAR T infusion, and 43 had follow-up PET/CT on day 30.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
